Effects of specific allergen immunotherapy on biological markers and clinical parameters in asthmatic children: a controlled-real life study.

Q2 Medicine

Clinical and Molecular Allergy Pub Date : 2017-04-03 eCollection Date: 2017-01-01 DOI:10.1186/s12948-017-0064-5

I Djuric-Filipovic, Marco Caminati, D Filipovic, C Salvottini, Z Zivkovic

{"title":"Effects of specific allergen immunotherapy on biological markers and clinical parameters in asthmatic children: a controlled-real life study.","authors":"I Djuric-Filipovic, Marco Caminati, D Filipovic, C Salvottini, Z Zivkovic","doi":"10.1186/s12948-017-0064-5","DOIUrl":null,"url":null,"abstract":"Background: Allergen-specific immunotherapy (AIT) is the only treatment able to change the natural course of allergic diseases. We aimed at investigating the clinical efficacy of SLITOR (Serbian registered vaccine for sublingual allergen specific immunotherapy).Methods: 7-18 years old children with allergic asthma and rhinitis were enrolled and addressed to the active (AIT plus pharmacological treatment) or control (standard pharmacological treatment only) group. Clinical and medications scores, lung function and exhaled FeNO were measured at baseline and at every follow-up.Results: There was a significant improvement in both nasal and asthma symptom scores as well as in medication score in SLIT group. SLIT showed an important influence on lung function and airway inflammation.Conclusions: Our data showed that SLITOR was effective not only in terms of patient reported outcomes but an improvement of pulmonary function and decrease of lower airway inflammation were also observed.","PeriodicalId":38753,"journal":{"name":"Clinical and Molecular Allergy","volume":"15 ","pages":"7"},"PeriodicalIF":0.0000,"publicationDate":"2017-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12948-017-0064-5","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Molecular Allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12948-017-0064-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 14

Abstract

Background: Allergen-specific immunotherapy (AIT) is the only treatment able to change the natural course of allergic diseases. We aimed at investigating the clinical efficacy of SLITOR (Serbian registered vaccine for sublingual allergen specific immunotherapy).

Methods: 7-18 years old children with allergic asthma and rhinitis were enrolled and addressed to the active (AIT plus pharmacological treatment) or control (standard pharmacological treatment only) group. Clinical and medications scores, lung function and exhaled FeNO were measured at baseline and at every follow-up.

Results: There was a significant improvement in both nasal and asthma symptom scores as well as in medication score in SLIT group. SLIT showed an important influence on lung function and airway inflammation.

Conclusions: Our data showed that SLITOR was effective not only in terms of patient reported outcomes but an improvement of pulmonary function and decrease of lower airway inflammation were also observed.

Abstract Image

查看原文本刊更多论文

特异性过敏原免疫治疗对哮喘儿童生物标志物和临床参数的影响:一项对照现实生活研究。

背景:过敏原特异性免疫治疗(AIT)是唯一能够改变变态反应性疾病自然进程的治疗方法。我们的目的是研究SLITOR(塞尔维亚注册的舌下过敏原特异性免疫治疗疫苗)的临床疗效。方法:选取7-18岁的变应性哮喘和鼻炎患儿，分为活动组(AIT +药物治疗)和对照组(仅标准药物治疗)。在基线和每次随访时测量临床和药物评分、肺功能和呼气FeNO。结果:SLIT组患者鼻、哮喘症状评分及用药评分均有显著改善。SLIT对肺功能和气道炎症有重要影响。结论:我们的数据显示，SLITOR不仅在患者报告的结果方面有效，而且还观察到肺功能的改善和下气道炎症的减少。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Molecular Allergy Medicine-Immunology and Allergy

CiteScore

8.20

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Clinical and Molecular Allergy is an open access, peer-reviewed, online journal that publishes research on human allergic and immunodeficient disease (immune deficiency not related to HIV infection/AIDS). The scope of the journal encompasses all aspects of the clinical, genetic, molecular and inflammatory aspects of allergic-respiratory (Type 1 hypersensitivity) and non-AIDS immunodeficiency disorders. However, studies of allergic/hypersensitive aspects of HIV infection/AIDS or drug desensitization protocols in AIDS are acceptable. At the basic science level, this includes original work and reviews on the genetic and molecular mechanisms underlying the inflammatory response.